Core Insights - Profusa, Inc. is expanding its customer base in Europe through a collaboration with AZ Sint Blasius Hospital in Belgium, led by Dr. Koen Deloose, a recognized expert in critical limb ischemia [1][3] - Dr. Deloose's clinic employs a multidisciplinary approach to treat patients, integrating specialists in diabetic foot care, wound care, and podiatry [2] - Profusa's Lumee Oxygen monitoring system is expected to enhance treatment outcomes for patients with critical limb ischemia by providing real-time tissue oxygen metrics [2][3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemical data [4] - The company aims to provide affordable, long-lasting biosensors that deliver actionable medical-grade data for both personal and clinical use [4] Leadership and Research - Dr. Koen Deloose has a significant background in vascular medicine, having authored over 200 articles in peer-reviewed journals and holding leadership roles in various medical organizations [2] - Profusa's CEO, Ben Hwang, emphasizes the alignment of Dr. Deloose's clinical work with the company's mission to improve health through accessible biochemical monitoring [3]

Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collabora ...

Core Insights - Profusa, Inc. has announced significant leadership changes, including the appointment of Peter O'Rourke as lead independent director and Fred Knechtel as Chief Financial Officer, following its business combination with NorthView Acquisition Corp [1][2] - The company is positioned at a critical juncture as it prepares to launch its innovative biosensor platform into global markets, with leadership bringing extensive experience in healthcare and finance [2][3] Leadership Appointments - Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, brings a wealth of experience overseeing a large healthcare system serving over 9 million veterans across 1,300 facilities [2][3] - Fred Knechtel has a strong background in finance and operations, having worked with various companies in sectors such as life sciences and automotive, and has been a trusted partner to Profusa [2][3][4] Company Vision and Technology - Profusa aims to revolutionize health monitoring through its biosensor technology, which is designed to provide continuous, actionable medical-grade data [4] - The company focuses on developing long-lasting, injectable biosensors that offer personalized biochemical signatures for both personal and medical use [4]